drugset / Trial / NCT00546923

Study Evaluating Venlafaxine Extended-Release in Depressed and Anxious Patients

NCT00546923

Phase 4 Completed 210 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

To examine the efficacy and safety of venlafaxine XR in the treatment of physical and emotional symptoms in patients with an operationally-defined diagnosis of multisomatoform disorder (MSD).

Timeline

Start
2004-08
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Venlafaxine Small molecule